NO311494B1 - Doseringsform for behandling av mikrobiologiske tilstander i mennesker eller dyr, fremgangsmåte for sterilisering av engjenstand, steriliserende blanding, samt dyrefôrtillegg - Google Patents
Doseringsform for behandling av mikrobiologiske tilstander i mennesker eller dyr, fremgangsmåte for sterilisering av engjenstand, steriliserende blanding, samt dyrefôrtillegg Download PDFInfo
- Publication number
- NO311494B1 NO311494B1 NO19963446A NO963446A NO311494B1 NO 311494 B1 NO311494 B1 NO 311494B1 NO 19963446 A NO19963446 A NO 19963446A NO 963446 A NO963446 A NO 963446A NO 311494 B1 NO311494 B1 NO 311494B1
- Authority
- NO
- Norway
- Prior art keywords
- acidifying agent
- source
- pharmaceutically acceptable
- dosage form
- nitrite ions
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 18
- 230000001954 sterilising effect Effects 0.000 title claims abstract description 15
- 239000002552 dosage form Substances 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 title claims abstract description 8
- 230000002906 microbiologic effect Effects 0.000 title claims description 6
- 239000006052 feed supplement Substances 0.000 title abstract 2
- 238000004659 sterilization and disinfection Methods 0.000 title 1
- 239000002535 acidifier Substances 0.000 claims abstract description 23
- 239000003937 drug carrier Substances 0.000 claims abstract description 6
- -1 nitrite ions Chemical class 0.000 claims description 18
- 239000002243 precursor Substances 0.000 claims description 15
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 14
- 229910001963 alkali metal nitrate Inorganic materials 0.000 claims description 12
- 150000001340 alkali metals Chemical class 0.000 claims description 12
- 229910001964 alkaline earth metal nitrate Inorganic materials 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 7
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 7
- 229960004889 salicylic acid Drugs 0.000 claims description 7
- 239000013589 supplement Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 150000007524 organic acids Chemical group 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 241000282887 Suidae Species 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 230000009286 beneficial effect Effects 0.000 claims description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 abstract description 34
- 239000004599 antimicrobial Substances 0.000 abstract description 3
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002538 fungal effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 28
- 229910002651 NO3 Inorganic materials 0.000 description 17
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 17
- 239000002253 acid Substances 0.000 description 15
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 12
- 230000000694 effects Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 235000010288 sodium nitrite Nutrition 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229910017604 nitric acid Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- 208000005577 Gastroenteritis Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 235000019647 acidic taste Nutrition 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 206010001986 Amoebic dysentery Diseases 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 108010033478 E coli K88 antigen Proteins 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- MBMLMWLHJBBADN-UHFFFAOYSA-N Ferrous sulfide Chemical compound [Fe]=S MBMLMWLHJBBADN-UHFFFAOYSA-N 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 102000005298 Iron-Sulfur Proteins Human genes 0.000 description 1
- 108010081409 Iron-Sulfur Proteins Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241001137872 Leishmania sp. Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241001467578 Microbacterium Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 241001147693 Staphylococcus sp. Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 244000000074 intestinal pathogen Species 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229940005654 nitrite ion Drugs 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 150000004005 nitrosamines Chemical class 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9403284A GB9403284D0 (en) | 1994-02-21 | 1994-02-21 | Acidified nitrite as antimicrobial agent |
| GB9404365A GB9404365D0 (en) | 1994-03-07 | 1994-03-07 | Acidified nitrate as antimicrobial agent |
| PCT/GB1995/000338 WO1995022335A1 (fr) | 1994-02-21 | 1995-02-17 | Nitrite acidifie en tant qu'agent antimicrobien |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO963446D0 NO963446D0 (no) | 1996-08-19 |
| NO963446L NO963446L (no) | 1996-10-21 |
| NO311494B1 true NO311494B1 (no) | 2001-12-03 |
Family
ID=26304368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19963446A NO311494B1 (no) | 1994-02-21 | 1996-08-19 | Doseringsform for behandling av mikrobiologiske tilstander i mennesker eller dyr, fremgangsmåte for sterilisering av engjenstand, steriliserende blanding, samt dyrefôrtillegg |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0746327B1 (fr) |
| JP (1) | JP3875262B2 (fr) |
| KR (1) | KR100385297B1 (fr) |
| CN (1) | CN1145491C (fr) |
| AT (1) | ATE264685T1 (fr) |
| AU (1) | AU693851B2 (fr) |
| BR (1) | BR9507099A (fr) |
| CA (1) | CA2183549C (fr) |
| CZ (1) | CZ286286B6 (fr) |
| DE (1) | DE69532921T2 (fr) |
| DK (1) | DK0746327T3 (fr) |
| ES (1) | ES2218541T3 (fr) |
| FI (1) | FI114852B (fr) |
| NO (1) | NO311494B1 (fr) |
| PL (1) | PL180769B1 (fr) |
| PT (1) | PT746327E (fr) |
| WO (1) | WO1995022335A1 (fr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6709681B2 (en) | 1995-02-17 | 2004-03-23 | Aberdeen University | Acidified nitrite as an antimicrobial agent |
| GB9804469D0 (en) * | 1998-03-02 | 1998-04-29 | Univ Aberdeen | Antiviral composition |
| SE9700617D0 (sv) * | 1997-02-21 | 1997-02-21 | Kjell Alving | New composition |
| EP1107781A2 (fr) | 1998-08-28 | 2001-06-20 | University Of Bath | Ameliorations du traitement des lesions |
| GB9905425D0 (en) * | 1999-03-09 | 1999-05-05 | Queen Mary & Westfield College | Pharmaceutical composition |
| GB0021317D0 (en) | 2000-08-30 | 2000-10-18 | Queen Mary & Westfield College | Transdermal pharmaceutical delivery composition |
| GB0022084D0 (en) * | 2000-09-08 | 2000-10-25 | Univ Aberdeen | Treatment of multiply antibiotic-resistant organisms |
| US6432077B1 (en) * | 2000-12-26 | 2002-08-13 | Sensormedics Corporation | Device and method for treatment of surface infections with nitric oxide |
| GB0119011D0 (en) | 2001-08-03 | 2001-09-26 | Univ Aberdeen | Treatment of nail infections |
| ATE429947T1 (de) | 2001-08-29 | 2009-05-15 | Pharmakodex Ltd | Vorrichtung zur topischen verabreichung |
| GB0125222D0 (en) * | 2001-10-19 | 2001-12-12 | Barts & London Nhs Trust | Composition for the treatment of microbial infections |
| JP5564158B2 (ja) | 2003-07-09 | 2014-07-30 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 亜硝酸塩によって特定の心臓血管状態を処置する方法 |
| JP2008529626A (ja) * | 2005-02-11 | 2008-08-07 | ノーラブズ エービー | 皮膚真菌症、特に爪真菌症を治療するデバイスおよびその製造方法 |
| WO2006125123A2 (fr) | 2005-05-19 | 2006-11-23 | University Of Cincinnati | Procedes pour le traitement d'infections des voies respiratoires chez un sujet utilisant du nitrite acidifie |
| EP3556401A1 (fr) | 2005-05-27 | 2019-10-23 | The University of North Carolina at Chapel Hill | Particules libérant de l'oxyde nitrique pour thérapie à base d'oxyde nitrique et applications biomédicales |
| GB0604319D0 (en) * | 2006-03-03 | 2006-04-12 | Optinose As | Nasal delivery |
| GB0607402D0 (en) * | 2006-04-12 | 2006-05-24 | Barts & London Nhs Trust | Therapeutic composition and use |
| GB0618711D0 (en) * | 2006-09-22 | 2006-11-01 | Univ Exeter | Agricultural treatment |
| ES2958410T3 (es) | 2009-08-21 | 2024-02-08 | Novan Inc | Geles tópicos |
| EP2467173B8 (fr) | 2009-08-21 | 2019-06-19 | Novan, Inc. | Pansements, procédés d'utilisation de ceux-ci et procédés de formation de ceux-ci |
| US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
| WO2012118829A2 (fr) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Xérogels libérant de l'oxyde nitrique modifiés par des groupements s-nitrosothiols tertiaires et procédés d'utilisation associés |
| TW201521805A (zh) * | 2013-10-31 | 2015-06-16 | Advanced Plasma Therapies Inc | 使用電漿狀態之氧化氮來治療醫療狀況與疾病之方法 |
| CN106604735A (zh) * | 2014-06-13 | 2017-04-26 | 奥里根股份有限公司 | 使用电浆状态的氧化氮来治疗动物的医疗状况与疾病的兽医方法 |
| RU2755947C2 (ru) * | 2014-12-05 | 2021-09-23 | Кэн Текнолоджиз, Инк. | Добавка к корму для животных и способ |
| WO2018237233A1 (fr) | 2017-06-23 | 2018-12-27 | Can Technologies, Inc. | Procédé d'amélioration de qualité de viande |
| AU2020286987A1 (en) | 2019-06-04 | 2021-12-16 | Thirty Respiratory Limited | Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract |
| BR112021023832A8 (pt) | 2019-06-04 | 2023-02-28 | Thirty Holdings Ltd | Métodos e composições para geração de óxido nítrico e usos dos mesmos |
| BR112022021436A2 (pt) | 2020-04-23 | 2023-01-17 | Thirty Respiratory Ltd | Métodos e composições para tratamento e combate da tuberculose |
| EP4138795A1 (fr) | 2020-04-23 | 2023-03-01 | Thirty Respiratory Limited | Oxyde nitrique ou compositions libérant de l'oxyde nitrique destinés à être utilisés dans le traitement du sars-cov et du sars-cov-2 |
| GB202101543D0 (en) | 2021-02-04 | 2021-03-24 | Thirty Respiratory Ltd | Vaping e-liquid composition and the use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4191750A (en) * | 1976-03-08 | 1980-03-04 | Milton Hodosh | Method for treating canker sores |
| JPS5985278A (ja) * | 1982-11-05 | 1984-05-17 | Agency Of Ind Science & Technol | 食品の保存方法及び保存材 |
| JPH0622540B2 (ja) * | 1985-12-18 | 1994-03-30 | 株式会社祥光化学研究所 | 消臭抗菌能を有する構造物 |
-
1995
- 1995-02-17 PT PT95908347T patent/PT746327E/pt unknown
- 1995-02-17 CZ CZ19962456A patent/CZ286286B6/cs not_active IP Right Cessation
- 1995-02-17 WO PCT/GB1995/000338 patent/WO1995022335A1/fr active IP Right Grant
- 1995-02-17 DK DK95908347T patent/DK0746327T3/da active
- 1995-02-17 BR BR9507099A patent/BR9507099A/pt not_active IP Right Cessation
- 1995-02-17 DE DE69532921T patent/DE69532921T2/de not_active Expired - Lifetime
- 1995-02-17 EP EP95908347A patent/EP0746327B1/fr not_active Expired - Lifetime
- 1995-02-17 CA CA002183549A patent/CA2183549C/fr not_active Expired - Fee Related
- 1995-02-17 CN CNB951921991A patent/CN1145491C/zh not_active Expired - Fee Related
- 1995-02-17 PL PL95316033A patent/PL180769B1/pl not_active IP Right Cessation
- 1995-02-17 AU AU16699/95A patent/AU693851B2/en not_active Ceased
- 1995-02-17 ES ES95908347T patent/ES2218541T3/es not_active Expired - Lifetime
- 1995-02-17 JP JP52166995A patent/JP3875262B2/ja not_active Expired - Lifetime
- 1995-02-17 AT AT95908347T patent/ATE264685T1/de not_active IP Right Cessation
- 1995-02-17 KR KR1019960704590A patent/KR100385297B1/ko not_active IP Right Cessation
-
1996
- 1996-08-16 FI FI963232A patent/FI114852B/fi active IP Right Grant
- 1996-08-19 NO NO19963446A patent/NO311494B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100385297B1 (ko) | 2003-10-10 |
| NO963446D0 (no) | 1996-08-19 |
| ES2218541T3 (es) | 2004-11-16 |
| EP0746327A1 (fr) | 1996-12-11 |
| CA2183549A1 (fr) | 1995-08-24 |
| DE69532921D1 (de) | 2004-05-27 |
| PT746327E (pt) | 2004-06-30 |
| BR9507099A (pt) | 1997-09-16 |
| ATE264685T1 (de) | 2004-05-15 |
| NO963446L (no) | 1996-10-21 |
| FI963232A (fi) | 1996-09-12 |
| CZ245696A3 (en) | 1997-01-15 |
| FI114852B (fi) | 2005-01-14 |
| WO1995022335A1 (fr) | 1995-08-24 |
| PL180769B1 (pl) | 2001-04-30 |
| EP0746327B1 (fr) | 2004-04-21 |
| CZ286286B6 (cs) | 2000-03-15 |
| AU693851B2 (en) | 1998-07-09 |
| CN1144484A (zh) | 1997-03-05 |
| JP3875262B2 (ja) | 2007-01-31 |
| DK0746327T3 (da) | 2004-05-10 |
| AU1669995A (en) | 1995-09-04 |
| CA2183549C (fr) | 2006-09-12 |
| FI963232A0 (fi) | 1996-08-16 |
| DE69532921T2 (de) | 2005-04-14 |
| CN1145491C (zh) | 2004-04-14 |
| JPH09508921A (ja) | 1997-09-09 |
| PL316033A1 (en) | 1996-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO311494B1 (no) | Doseringsform for behandling av mikrobiologiske tilstander i mennesker eller dyr, fremgangsmåte for sterilisering av engjenstand, steriliserende blanding, samt dyrefôrtillegg | |
| US6709681B2 (en) | Acidified nitrite as an antimicrobial agent | |
| Chaveerach et al. | In vitro study on the effect of organic acids on Campylobacter jejuni/coli populations in mixtures of water and feed | |
| EP3125952B1 (fr) | Compositions stables d'iode non complexée et leurs procédés d'utilisation | |
| Buts et al. | Effects of Saccharomyces boulardii on intestinal mucosa | |
| JP6708715B2 (ja) | 次亜塩素酸を含む抗微生物剤 | |
| EA007791B1 (ru) | Состав со стабилизированными окислительно-восстановительными свойствами и способ стабилизации окислительно-восстановительных свойств | |
| US9913862B2 (en) | Methods of treating gram-negative microbial infections | |
| Devhare et al. | Acid neutralizing capacity and antimicrobial potential of selected solvent extract from various indigenous plants | |
| US20200171077A1 (en) | Compositions and methods for treating and preventing bacterial infections | |
| AU721868B2 (en) | Antimicrobial composition and methods of use therefor | |
| CN111568919A (zh) | 一种含壳寡糖的抗幽门螺旋杆菌制剂 | |
| JP2002322079A (ja) | ピロリ菌除菌組成物及びピロリ菌抗菌、除菌剤 | |
| GB2275194A (en) | Plant Extract Disinfectant | |
| EP3797761A1 (fr) | Composition bactéricide non pharmaceutique contre l'helicobacter pylori | |
| Urata et al. | Comparison of the microbicidal activities of superoxidized and ozonated water in the disinfection of endoscopes | |
| CN112569225B (zh) | 非药物幽门杆菌杀菌组合物 | |
| Rangel-Vargas et al. | A natural approach to combating antibiotic-resistant pathogens in livestock: Hibiscus sabdariffa-derived hibiscus acid as a promising solution | |
| Chen et al. | Development of an eco-sustainable formulation against Streptococcus mutans and Candida albicans | |
| SATOH et al. | Therapy for urolithiasis with hydroxamic acids. IV. Prevention of infected urinary stone formation with N-(pivaloyl) glycinohydroxamic acid | |
| CN118252873A (en) | Povidone-iodine solution for disinfecting chickens and preparation method thereof | |
| Ross | Modes of action of antimicrobial garlic derivatives | |
| KR19990048645A (ko) | 가습기용 레지오넬라 살균소독제 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |